Drug Design

According to the official website of the University of Cambridge in the UK, researchers at the university have greatly accelerated the development of treatments for Parkinson's disease through artificial intelligence technology. The researchers designed and used an AI-based strategy to identify small molecules that prevent the aggregation of alpha-synuclein (IT Home Note: a characteristic protein of Parkinson's disease). This is also a way to find potential treatments for Parkinson's disease. The team used machine learning technology to quickly screen a chemical library containing millions of entries to identify small molecules that bind to amyloid aggregates and prevent their proliferation, and ultimately identified 5 highly effective compounds...